CureMetrix wins FDA nod for mammo AI triage software
Breast imaging computer-aided detection software developer CureMetrix has garnered...Read more on AuntMinnie.comRelated Reading: Mammo AI software yields workflow, economic benefits AI-based CAD software improves breast cancer detection CureMetrix to provide DocPanel with AI mammo software CureMetrix delivers CAD software to Mexican clinic CureMetrix adds to medical advisory board
This study aimed to evaluate immunohistochemical expression of cyclin D1 and PSA in breast carcinoma and their relation to prognosis. It includes 79 specimens of breast invasive duct carcinoma. Overall survival time was available for all patients. There is a statistically significant association between positive PSA expression and lower tumor stage, nodal stage and tumor grade and between negative PSA expression and presence of metastasis (P value = .05, 0.01, 0.03 and 0.011, respectively). There is a highly statistically significant association between low percentage of cyclin D1 expression (
Authors: Akiki M, Haddad FG, Kourie HR, Khaddage A, Smayra VT PMID: 31631684 [PubMed - as supplied by publisher]
In conclusion, the present data demonstrated that GPER promoted proliferation, migration and invasion of TNBC cells through CAF. Furthermore, GPER expression was positively related to the prognosis of TNBC. PMID: 31632554 [PubMed]
Authors: Yang Y, Zheng H, Zhan Y, Fan S Abstract Traditionally, the metastasis has been detected in the late stage of the cancer, which mostly leads to death. The classical opinion about tumor metastasis is that tumor cell migration begins with the single tumor cell and goes through a series of complicated procedures, and lastly arrives and survives at distant tissues and organs. However, emerging studies have found a new migration mechanism called collective cell migration in many cancers. The collective cell migration could move as clusters with the tight cell-cell junction in the tumor microenvironments, toward ...
Authors: Branco FP, Machado D, Silva FF, André S, Catarino A, Madureira R, Pinto JM, Godinho JP, Simões PD, Brito M, Casa-Nova M, Moreira AR, Passos-Coelho JL Abstract INTRODUCTION: HER2 overexpression/amplification occurs in 15-20% breast cancers (BC) and is associated with worse prognosis. The addition of anti-HER2 treatment to neoadjuvant chemotherapy significantly improves the pathological complete response (pCR) rate. Changes in HER2 status after neoadjuvant treatment (NAT) have been reported and may affect prognosis. The aim of this study was to assess the efficacy of NAT in patients with HER2+ ...
Authors: Huang D, Tang L, Yang F, Jin J, Guan X Abstract p110α is an important subunit of phosphatidylinositol-3-kinases (PI3Ks) encoded by PIK3CA. Though PI3Ks are known as crucial regulators of cellular growth and proliferation, the function of PIK3CA mutations in fulvestrant resistance remains elusive. Thus, this study aimed to investigate the roles of PIK3CA mutations in fulvestrant resistance and tumor progression. Using circulating tumor DNA (ctDNA) from four fulvestrant-resistant patients, we found three of them were PIK3CA mutated, one with a novel PIK3CA mutation (p.R115P). In vitro experiments furth...
ConclusionESR1 mutations are not uncommon phenomenon in patients with hormone-sensitive advanced breast cancer. There is a significant higher incidence rate of ESR1 mutations in patients with previous AI-containing therapeutic regimens, compared to those who received non-AI containing regimes. These ESR1 mutations could lead to the development of complete endocrine resistance to AI, whereas only partial resistance is seen in case of TAM or FUL.
A thermal imaging camera in Edinburgh showed that a Slough visitor's breast was a different colour.
The NHS invites women aged 50 to 70 for breast screening every three years, but evidence suggests up to 30 per cent of those who attend will get breast cancer between appointments.
Bal Gill, 41, was visiting World of Illusions in Edinburgh during a family holiday in May. A thermal camera showed a hot spot in her left breast that no one else had.